Teva Keeps On Buying

BMI View: Teva Pharmaceutical Industries continues to favour inorganic growth from mergers and acquisitions (M&A) over in-house research and development (R&D). However, large debts from acquisitions, below consensus sales results, below-expectation clinical results for Laquinimod and the possibility that the company will face generic competition for its biggest blockbuster drug - Copaxone (glatiramer acetate) - before its official patent expiration in 2014, has worried investors.

To read the full article, please choose one of the following options: